Interaction of the human prostacyclin receptor with Rab11: characterization of a novel Rab11 binding domain within alpha-helix 8 that is regulated by palmitoylation.
The human prostacyclin receptor (hIP) undergoes agonist-induced internalization and subsequent recyclization in slowly recycling endosomes involving its direct physical interaction with Rab11a. Moreover, interaction with Rab11a localizes to a 22-residue putative Rab11 binding domain (RBD) within the carboxyl-terminal tail of the hIP, proximal to the transmembrane 7 (TM7) domain. Because the proposed RBD contains Cys(308) and Cys(311), in addition to Cys(309), that are known to undergo palmitoylation, we sought to identify the structure/function determinants of the RBD, including the influence of palmitoylation, on agonist-induced trafficking of the hIP. Through complementary approaches in yeast and mammalian cells along with computational structural studies, the RBD was localized to a 14-residue domain, between Val(299) and Leu(312), and proposed to be organized into an eighth alpha-helical domain (alpha-helix 8), comprising Val(299)-Val(307), adjacent to the palmitoylated residues at Cys(308)-Cys(311). From mutational and [(3)H]palmitate metabolic labeling studies, it is proposed that palmitoylation at Cys(311) in addition to agonist-regulated deacylation at Cys(309) > Cys(308) may dynamically position alpha-helix 8 in proximity to Rab11a, to regulate agonist-induced intracellular trafficking of the hIP. Moreover, Ala-scanning mutagenesis identified several hydrophobic residues within alpha-helix 8 as necessary for the interaction with Rab11a. Given the diverse membership of the G protein-coupled receptor superfamily, of which many members are also predicted to contain an alpha-helical 8 domain proximal to TM7 and, often, adjacent to palmitoylable cysteine(s), the identification of a functional role for alpha-helix 8, as exemplified as an RBD for the hIP, is likely to have broader significance for certain members of the superfamily.
Reid
Helen M
HM
School of Biomolecular and Biomedical Sciences, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland.
Mulvaney
Eamon P
EP
Turner
Elizebeth C
EC
Kinsella
B Therese
BT
D019295:Computational Biology / Q000379:methods; D003545:Cysteine / Q000737:chemistry; D006801:Humans; D007930:Leucine / Q000737:chemistry; D019308:Palmitic Acid / Q000737:chemistry; D010169:Palmitic Acids / Q000737:chemistry*; D011453:Prostaglandins / Q000737:chemistry; D011485:Protein Binding; D017433:Protein Structure, Secondary; D017434:Protein Structure, Tertiary; D021381:Protein Transport; D044006:Receptors, Epoprostenol / Q000737:chemistry*; D043562:Receptors, G-Protein-Coupled / Q000378:metabolism; D014633:Valine / Q000737:chemistry; D020691:rab GTP-Binding Proteins / Q000737:chemistry*; D000099193:rab11 GTP-Binding Proteins
D003545:Cysteine; D007930:Leucine; D019308:Palmitic Acid; D010169:Palmitic Acids; D011453:Prostaglandins; D044006:Receptors, Epoprostenol; D043562:Receptors, G-Protein-Coupled; D014633:Valine; D020691:rab GTP-Binding Proteins; D000099193:rab11 GTP-Binding Proteins
Br J Pharmacol. 2004 Sep;143(2):318-30
15339863
J Biol Chem. 1999 Aug 20;274(34):23707-18
10446129
J Biol Chem. 2005 Oct 28;280(43):36195-205
16126723
Eur J Biochem. 1991 Jun 1;198(2):357-64
1645656
Trends Biochem Sci. 1995 May;20(5):181-7
7610481
J Cell Sci. 2007 Dec 1;120(Pt 23):4197-208
18003705
Methods. 2006 Oct;40(2):191-7
17012032
Nat Rev Mol Cell Biol. 2009 Apr;10(4):287-92
19277045
Biochim Biophys Acta. 2004 May 27;1663(1-2):74-81
15157609
J Mol Biol. 2010 Feb 26;396(3):473-86
20070947
J Biol Chem. 2000 Oct 13;275(41):32037-45
10889200
J Pharmacol Exp Ther. 1997 May;281(2):957-64
9152406
Proteins. 2007;69 Suppl 8:108-17
17894355
Mol Biol Cell. 2001 Jun;12(6):1843-57
11408590
Dev Cell. 2007 Oct;13(4):496-510
17925226
Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):109-18
17164138
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W197-201
18463136
J Biol Chem. 2005 Apr 22;280(16):15485-8
15746102
Mol Biol Cell. 2004 May;15(5):2456-69
15004234
Science. 2004 Dec 10;306(5703):1954-7
15550624
BMC Bioinformatics. 2008 Jan 23;9:40
18215316
Pharmacol Rep. 2008 Jan-Feb;60(1):3-11
18276980
Circulation. 2001 Oct 30;104(18):2210-5
11684633
Biochim Biophys Acta. 1998 Dec 8;1436(1-2):245-61
9838145
Am J Cardiol. 1995 Jan 19;75(3):3A-10A
7840052
Science. 2008 Nov 21;322(5905):1211-7
18832607
J Cell Sci. 2007 Nov 15;120(Pt 22):3905-10
17989088
Biochem Pharmacol. 2009 Jul 1;78(1):11-20
19447219
Science. 2000 Aug 4;289(5480):739-45
10926528
Cell Signal. 2007 May;19(5):1056-70
17229546
Cancer Res. 2005 Apr 1;65(7):2516-9
15805241
J Biol Chem. 2003 Feb 28;278(9):6947-58
12488443
J Biol Chem. 2006 May 5;281(18):12896-907
16500896
J Cell Biol. 2008 Oct 6;183(1):143-55
18838556
J Biol Chem. 2004 Oct 8;279(41):43027-34
15292201
Hypertension. 1995 Apr;25(4 Pt 2):726-30
7721423
Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2840-5
10077598
Cell Signal. 2008 Dec;20(12):2332-46
18832025
Life Sci. 1990;47(8):711-9
2119471
DNA Cell Biol. 1992 Jan-Feb;11(1):1-20
1310857
Life Sci. 2003 Dec 5;74(2-3):225-35
14607250
J Biol Chem. 2000 Jan 21;275(3):1937-43
10636895
Biochemistry. 1999 Mar 16;38(11):3447-55
10079092
J Biol Chem. 2001 Sep 7;276(36):33596-607
11443126
Nat Med. 2004 Nov;10(11):1251-6
15502842
Mediators Inflamm. 2007;2007:10767
17710245
Biochem J. 2005 Feb 15;386(Pt 1):177-89
15469414
J Biol Chem. 1999 Sep 3;274(36):25517-24
10464283
Biochim Biophys Acta. 2007 Apr;1768(4):808-24
17097603
Mol Biol Cell. 2004 Apr;15(4):2038-47
14767056
Traffic. 2007 Apr;8(4):414-30
17394487
Physiol Rev. 1999 Oct;79(4):1193-226
10508233
Br J Pharmacol. 2004 Sep;143(2):292-302
15326037
Biochem J. 2009 Feb 15;418(1):163-72
18983266
Arthritis Res Ther. 2005;7 Suppl 4:S14-22
16168077
Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):272-7
9874808
Biochim Biophys Acta. 2008 Oct;1783(10):1914-28
18498773
Br J Pharmacol. 2001 Apr;132(8):1639-49
11309234
Eur J Biochem. 2002 Mar;269(6):1714-25
11895442
Am J Physiol Cell Physiol. 2001 Jun;280(6):C1375-86
11350732